- News
- Announcements
Announcements
Current & archive
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you five new Fact Sheets.
Fact Sheet No. 146 (September 2023)
Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma
Fact Sheet No. 147 (September 2023)
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation
Fact Sheet No. 148 (September 2023)
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)
Fact Sheet No. 149 (September 2023)
Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM)
Fact Sheet No. 150 (September 2023)
Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)
Economic Dimensions of Community Nursing: A Systematic Literature Review
Community Nursing is a new model of care in Austria to strengthen the health of the elderly population. The literature review examines the cost-effectiveness of the concept and methods for presenting it. The results are inconclusive. The use of community nursing tends not to be cost-effective in the eleven identified studies, but methodological limitations may have biased the results. The studies are also older and largely not from Europe. Further research using more recent methodological findings from research on complex interventions and evaluation of public health interventions is needed.
Publication: HTA Project Report No. 153: https://eprints.aihta.at/1470/
Contact: Ingrid Zechmeister-Koss
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you eight new Fact Sheets.
Fact Sheet No. 138 (August 2023)
Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)
Fact Sheet No. 139 (August 2023)
Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 140 (August 2023)
Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer
Fact Sheet No. 141 (August 2023)
Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 142 (August 2023)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Fact Sheet No. 143 (August 2023)
Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)
Fact Sheet No. 144 (August 2023)
Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease
Fact Sheet No. 145 (August 2023)
Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
Robot-assisted surgery in thoracic and visceral indications – Update 2023
Robotic-assisted surgery represents a technically advanced form of a minimally invasive procedure that claims to improve clinical outcomes as well as healthcare resource utilization. This report is an update of a systematic review from 2019, which examined the effectiveness and safety of robotic-assisted surgery in thoracic and visceral indications, compared to open surgery and conventional laparoscopy. In total, 14 indications were investigated, with no evidence identified for five indications. Due to the heterogeneous results and lack of evidence for some study endpoints, a general statement on the effectiveness and safety of robotic-assisted surgery is not possible.
Publication: HTA Project Report No. 108: https://eprints.aihta.at/1461
Contact : Nicole Grössmann-Waniek
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 135 (July 2023)
Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 136 (July 2023)
Trifluridine / tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)
Fact Sheet No. 137 (July 2023)
Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer
Evaluation of individual medical procedures - Reports 2023
We are pleased to introduce our new reports.
Decision Support Documents 2023:
- DSD 135: Percutaneous aspiration thrombectomy for pulmonary embolism https://eprints.aihta.at/1454/
- DSD 136: Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor https://eprints.aihta.at/1455/
- DSD 137: Bleomycin Electrosclerotherapy for Vascular Anomalies: Systematic Review https://eprints.aihta.at/1456/
- DSD 138: Electrical auricular vagus nerve stimulation for pain https://eprints.aihta.at/1457/
+ 3 Updates
- DSD 41: Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. 2nd Update 2023 https://eprints.aihta.at/1451/
- DSD 111: Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas. 1st Update 2023 https://eprints.aihta.at/1452/
- DSD 118: 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023 https://eprints.aihta.at/1453/
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 130 (May 2023)
Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Fact Sheet No. 131 (May 2023)
Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)
Fact Sheet No. 132 (May 2023)
Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 133 (May 2023)
Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC)
Fact Sheet No. 134 (May 2023)
Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 129 (April 2023)
Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)
Sponsoring of patient initiatives in Austria.5th Update of the Systematic Analyses 2014 to 2019
As patient initiatives expand their activities and continue to professionalise, their need for financial resources, which often gets bankrolled by pharma-ceutical companies, increases accordingly. To make these financial transactions more transparent, the pharmaceutical industry responded with volun-tary disclosure commitments. AIHTA (then still as LBI-HTA) systematical-ly analysed the content of these voluntary disclosures of sponsorship for pa-tient initiatives by members of the Association of Austria’s Pharmaceutical Industry (PHARMIG - Verband der pharmazeutischen Industrie Österreichs) for the first time in 2014 and aims to carry out regular and consistent moni-toring of these payments. The present fifth update systematically researched the extent of financial support to patient initiatives disclosed by member companies of PHARMIG for the fiscal year of 2021.
Publication: Policy Brief No. 007/5. Update: https://eprints.aihta.at/1443/
Contakt: Claudia Wild
